Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected females (gender at birth) \>=18 years of age~* Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol)~* HIV-1 infection as documented by Screening plasma HIV-1 RNA \>=500 c/mL.~* Documentation that the subject is negative for the HLA-B\*5701 allele.~* Antiretroviral-naïve (\<=10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection).~* Signed and dated written informed consent is obtained from the subject or the subject's legal representative prior to screening.~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* Women who plan to become pregnant during the first 48 weeks of the study~* Any subject who has had a medical intervention for gender reassignment~* Any evidence of an active Centers for Disease Control and Prevention (CDC) Category C disease~* Subjects with any degree of hepatic impairment~* Subjects positive for hepatitis B at Screening, or anticipated need for HCV therapy during the study~* History or presence of allergy to the study drugs or their components or drugs of their class~* Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia~* poses a significant suicidality risk~* History of osteoporosis with fracture or requiring pharmacologic therapy~* Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening~* Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses;~* Treatment with any agent, with documented activity against HIV-1 in vitro within 28 days of first dose of investigational product (IP)~* Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP~* Any evidence of primary viral resistance based on the presence of any major resistance-associated mutation in the Screening result or, if known, any historical resistance test result~* Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 lipid abnormalities (total cholesterol, triglycerides, High Density Lipoprotein (HDL) cholesterol, Low Density Lipoprotein (LDL) cholesterol)~* Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an investigational compound~* Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN), or ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with \>35% direct bilirubin)~* Subject has CrCL of \<50 mL/min via Cockroft-Gault method~* Corrected QT interval (QTc (Bazett)) ≥450msec or QTc (Bazett) ≥480msec for subjects with bundle branch block.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DTG/ABC/3TC FDC (Type: EXPERIMENTAL): As per the randomization schedule subjects will be administered with DTG/ABC/3TC (50mg/600mg/300mg) FDC tablet OD up to Week 48 and if continued if applicable in the Continuation Phase. DTG/ABC/3TC FDC may be administered with or without food
- ATV +RTV +TDF/FTC FDC (Type: ACTIVE_COMPARATOR): As per the randomization schedule subjects will be administered with ATV (300mg capsule) +RTV (100mg tablet) + TDF/FTC (300mg/200mg tablet) FDC OD up to Week 48. ATV+RTV+ TDF/FTC FDC must be taken with food

Based on this trial design, predict the completion outcome and termination type (if applicable).